TRexBio Secures $84M in Series B Funding to Propel Innovative Immunology Programs Toward Clinical Trials

TRexBio, a biotech company focused on developing cutting-edge treatments by studying immune cells in human tissues, has raised $84 million in a successful Series B funding round. The financing, which attracted more investor interest than expected, was led by Delos Capital with new support from Avego BioScience Capital and Agent Capital. Existing investors, including big names like Eli Lilly, Pfizer Ventures, Johnson & Johnson Innovation, SV Health Investors, Alexandria Venture Investments, and Polaris Partners, also participated in this round.

The funds will be directed toward advancing TRexBio’s lead drug candidate, TRB-061, which is being developed to treat immune-related diseases like atopic dermatitis and ulcerative colitis. TRB-061 specifically targets and activates certain immune cells in the skin and gut, called Tregs, that help control inflammation. The company plans to launch the first clinical trial for TRB-061 by mid-2025.

Additionally, this funding will allow TRexBio to expand its pipeline, including early development of another candidate, TRB-071. TRB-061 will become TRexBio's second clinical program, following its initial treatment, TRB-051, which is already in clinical testing in partnership with Eli Lilly. TRexBio is also collaborating with Johnson & Johnson on a preclinical program, marking a strong foundation of partnerships to support its innovative research.

Johnston Erwin, CEO of TRexBio, said in a statement, “We are grateful for the support and partnership of our investors, who share our vision for a differentiated approach to the treatment of autoimmune and inflammatory disease, one built on immune homeostasis rather than simply on suppression. The funding from this Series B financing enables us to enter the clinic early next year with TRB-061, and to start exploring the breadth of potential therapeutic applications for this novel therapy. We continue to believe that our unique, tissue-focused approach will enable first- and best-in-class programs with potential to address significant unmet patient need.”

“Regulatory T cells—and TRexBio’s lead program TRB-061 in particular—offer the potential to unlock a new pillar of therapeutic care for autoimmune and inflammatory diseases.

Dr. Eric Huang, said in a statement, Our goal at Delos is to invest in companies with strong scientific foundations and clear visions for changing clinical standards of care. We have been impressed by TRexBio’s rigorous scientific approach and innovative platform for harnessing the natural function of regulatory T cells to establish immune balance. We’re proud to support TRexBio’s work, which we believe will soon translate into safe, durable, and effective medicines that improve the lives of many patients.”

Alongside the new funding, TRexBio welcomed three new members to its Board of Directors: Dr. Eric Huang, Partner at Delos; Joel S. Marcus, Executive Chairman and Founder of Alexandria Venture Investments; and Dr. Eric Pham, Managing Director at Avego.